CD47 and ovarian carcinoma: Tumor regression and vascular normalization were observed in a syngeneic orthotopic mouse model of advanced-stage epithelial ovarian cancer treated daily with recombinant type 1 repeats (3TSR), including or without fusion to a CD47-binding sequence (FYVVMWK, 4N1), and expressed from adeno-associated virus (AAV) vectors [249].